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Clinical Relevancy Statement
Our study showed that children who have severe cerebral 
palsy (CP), with a gastrostomy and fundoplication, had 
significantly faster gastric emptying (GE) with whey-
based enteral formulas (either 50% whey or 100% whey) 
compared to a casein-based formula. Five of the 13 chil-
dren (39%) who had delayed GE with the casein formula, 
normalized with one of the whey-based formulas (using 
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the age-related reference range). Standard practice for 
enteral feeding has historically involved the use of casein-
based enteral formulas. In the scenario of a child with CP 
and delayed GE, a trial of a whey-based enteral formula 
may be warranted.
Introduction
Children with severe cerebral palsy (CP) commonly suf-
fer gastrointestinal (GI) dysfunction1,2 related to mal-
function of their enteric nervous system (ENS).3 
Malfunctions of their ENS can lead to conditions such 
as gastroesophageal reflux (GOR), delayed gastric emp-
tying (GE), and gastric dysrhythmias.4 GI dysfunction 
can contribute to symptoms of abdominal pain, diar-
rhea, regurgitation, vomiting, and constipation,5,6 which 
are often complications of enteral feeding in this popu-
lation. Furthermore, GI symptoms in a child with severe 
CP do not always receive appropriate medical attention 
because of the child’s inability to verbally communicate 
discomfort.7
Objectives: Children with severe cerebral palsy (CP) commonly 
have gastrointestinal (GI) dysfunction. Whey-based enteral 
formulas have been postulated to reduce gastroesophageal 
reflux (GOR) and accelerate gastric emptying (GE). The 
authors investigated whether whey-based (vs casein-based) 
enteral formulas reduce GOR and accelerate GE in children 
who have severe CP with a gastrostomy and fundoplication. 
Methods: Thirteen children received a casein-based formula for 
1 week and either a 50% whey whole protein (50% WWP) or a 
100% whey partially hydrolyzed protein (100% WPHP) formula 
for 1 week. Reflux episodes, gastric half-emptying time (GE 
t1/2), and reported pain and GI symptoms were measured. 
Results: Whey formulas emptied significantly faster than casein 
(median [interquartile range (IQR)] GE t1/2, 33.9 [25.3-166.2] 
min vs 56.6 [46-191] min; P = .033). Reflux parameters were 
unchanged. GI symptoms were lower in children who received 
50% WWP (visual analog symptom score, median [IQR], 0 
[0-11.8]) vs 100% WPHP (13.0 [2.5-24.8]) (P = .035). 
Conclusion: This pilot study shows that in children who have 
severe CP with a gastrostomy and fundoplication, GE of the 
whey-based enteral formula is significantly faster than casein. 
The acceleration in GE does not alter GOR frequency, and 
there appears to be no effect of whey vs casein in reducing acid, 
nonacid, and total reflux episodes. The results indicate that 
enteral formula selection may be particularly important for 
children with severe CP and delayed GE. (JPEN J Parenter 
Enteral Nutr. 2012;36:118S-123S)
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The incidence of GOR is higher in children with CP 
compared with the general population,4,6,8,9 and delayed 
GE is also common,2,10 with reports that 67% of children 
with CP and GOR have significantly delayed GE.5 Clinical 
manifestations include early satiety, nausea, vomiting, 
and retching, as well as an increased risk of aspiration.2
The few studies published in the area suggest that 
specific modification of the protein in the enteral formula 
may be a useful adjunct in the management of GI dysfunc-
tion in children with severe CP.11-14 Whey-based formulas 
(compared to casein) have been postulated to reduce 
GOR14 and accelerate GE.12,13 The purported benefits of 
whey protein relate to the predominance of β-lactoglobulin, 
which remains soluble in the stomach, therefore transiting 
more rapidly to the upper jejunum. Casein protein, in con-
trast, clots and or precipitates in the acid environment of 
the stomach, resulting in slower GE.15
The aim of this study was primarily to determine 
whether whey-based (vs casein-based) enteral formulas 
reduce GOR and accelerate GE in enterally fed children 
with severe CP. Second, we aimed to examine the effect 
of these formulas on symptoms of poor feed tolerance 
such as gagging, regurgitation, irritability, pain, and con-
stipation.
Methods
Study Population
Thirteen children (8 male, 5 female; mean age 7.2 years 
[range, 2.4-15.4 years]) with severe CP were enrolled. 
Eleven were of Caucasian background, 1 was of Asian 
descent, and 1 was of Aboriginal descent. Type of CP 
included 7 with spastic quadriplegia, 3 with spastic diple-
gia, 2 with hypotonia, and 1 with dyskinetic CP. All were 
100% enterally fed—12 via percutaneous endoscopic gas-
trostomy (PEG) tube and 1 via a nasogastric tube (NGT). 
All children except for the child receiving NGT feeds had 
undergone at least 1 fundoplication procedure (2 chil-
dren had undergone 2). They were fed via daytime 
boluses with or without overnight continuous feeds via a 
pump. Their feeding regime during the study was either 
identical or as close as possible to their usual regime—
this included factors such as frequency of feeds, total 
volume, and caloric/nutrient composition. All children 
were assessed by a pediatric dietitian as “nutritionally 
sound,” with their height appropriate for their weight 
percentile using Centers for Disease Control and 
Prevention (CDC) percentile charts. Height was mea-
sured using Knee Height Callipers (Ross Laboratories, 
Columbus, Ohio) and converted using the validated equa-
tion into height.16 Weight was measured either using 
standing scales (parent/caregiver holding child) or using 
wheelchair scales.
Children were recruited from the Women’s and 
Children’s Hospital Home Enteral Nutrition Database. 
Ethical approval was obtained from the Human Research 
Ethics Committee CYHWS (REC1997/9/10). All patients 
complied with the following inclusion criteria: (1) CP with 
severe neurological impairment graded by the Cerebral 
Palsy Gross Motor Function Classification Scale (levels 
4–5), (2) history of GOR, (3) 100% dependent on enteral 
nutrition (to prevent oral consumption of food proteins 
that may potentially confound results), (4) well matched 
for height/weight (to avoid any confounding affect of 
improved nutrition on GI function),17 (5) no concurrent 
use of antibiotics (due to their potential affect on GE), and 
(6) no GI surgery in past 3 months (as delayed GE may 
occur after surgical placement of a PEG tube).18
Medications
Because patients acted as their own controls, they all 
continued their usual medication regime throughout the 
entire study. Five patients were taking baclofen 
(Alphapharm Pty Ltd, Glebe NSW, Australia, and Apotex 
Pty Ltd, North Ryde, NSW, Australia), and 3 were taking 
omeprazole (AstraZeneca, North Ryde NSW, Australia).
Study Design and Investigations
This pilot study was a randomized, double-blind, cross-
over clinical trial in which children received a standard 
casein-based enteral formula (Pediasure [82% casein, 
18% whey]; Abbott Australasia, NSW, Australia) for 1 
week and either a 50% whey, 50% casein whole-protein 
(50% WWP) formula (Nutren Junior; Nestle Clinical 
Nutrition, Vevey, Switzerland) for 1 week (n = 7) or a 
100% whey partially hydrolyzed protein (100% WPHP) 
formula (Peptamen Junior; Nestle Clinical Nutrition) for 
1 week (n = 6). Order of casein vs whey formula was also 
randomized. Each patient served as his or her own control 
for paired comparison. There was no washout between 
different formulas as patients were given each formula for 
6–7 days prior to testing.
Multichannel Intraluminal Impedance With 
pH-metry
On days 6–7 of each week, a multichannel intraluminal 
impedance (MII) ambulatory data logger (Sleuth; Sandhill 
Scientific, Littleton, CO) was used to perform esophageal 
pH-MII monitoring studies (acid and nonacid reflux). A 
ComforTech Infant catheter (Sandhill Scientific, Denver, 
CO), with 6 impedance segments (1.5-cm spacing) and a 
pH sensor located at the distal segment, was used. After 
calibration and intubation, correct position (between T6 
and T8) of the pH sensor was confirmed by a lateral chest 
X-ray. Parents/guardians were instructed to maintain normal 
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daily routines. The catheter remained in situ for a mini-
mum of 20 hours and a maximum of 24 hours. Children 
continued their normal enteral feed regime during this 
time. At the completion of the study, the information 
recorded on the data logger was downloaded and the trac-
ings were manually analyzed using semi-automated imped-
ance analysis software (Bioview; Sandhill Scientific) to 
determine the occurrence of acid and nonacid reflux. 
Liquid GOR episodes were identified by a decrease in 
impedance of at least 50% from baseline traveling retro-
grade in the esophageal body. The proximal extent of reflux 
was defined by the most proximal impedance channel 
demonstrating an impedance drop of >50% from baseline. 
For each impedance-detected GOR episode, the pH of the 
refluxate was determined by the esophageal pH sensor. 
Reflux episodes were defined according to esophageal pH 
as acidic (pH <4) or nonacidic (pH ≥7). Acid reflux index 
(% time pH <4) was determined using automated analysis 
of the pH tracing (GERD Check; Sandhill Scientific).
Gastric Emptying
On day 6 of each week, GE rate was measured using the 
13C-Na-octanoate breath test using 13C-labeled Na-octanoate 
(50 mg, 99% enrichment; Cambridge Isotope Laboratories, 
Andover, MA). Patients were fasted overnight and then given 
a 200-mL bolus of either the casein or whey formula contain-
ing 100 mg 13C-Na-octanoate for breath test measurement of 
liquid GE. Breath samples were taken using a small flexible 
tube connected to a syringe, which was held in close proxim-
ity to the patient’s mouth or nose as he or she breathed out. 
Samples were taken before the bolus and afterward at 5-min-
ute intervals until 30 minutes and 15-minute intervals until 
4 hours. Patients remained recumbent in their wheelchair, in 
a pram, or on a hospital bed for the 4-hour study period. 
Breath samples were analyzed for 13CO2 content using an 
isotope ratio mass spectrometer (IRMS; Europa Scientific, 
ABCA 20/20, Crewe, UK), and the 13CO2 excretion rate 
curves were used to calculate the gastric half-emptying time 
(GE t1/2) using an established nonlinear regression model.
19 
Age-related reference ranges20 for liquid GE t1/2 were then 
used to compare GE with various formulas.
Symptoms
Symptoms were reported by parents throughout the study 
using 3 methods:
1. Parent recording sheet (completed at home for the 
2-week duration of the study)
2. Visual analog scale (VAS) questionnaire for 5 symp-
toms (gagging, regurgitation, irritability, pain, and 
constipation). Scoring for each symptom involved 
placing a mark along a 10-cm line (far left indicating 
no symptom and far right indicating severe symptom).
3. A Non-Communicative Children’s Pain Checklist 
(NCCPC)21
The latter 2 were completed by the parent/caregiver 
when visiting the hospital for testing on day 6 of each week.
Study Formulas
The casein formula and 2 whey formulas were compara-
ble with respect to calories, protein, carbohydrates, fat 
concentration, and osmolality (information provided by 
manufacturer). They were all lactose free with very simi-
lar carbohydrate sources. Aside from the protein type and 
fractionation, the only other difference was the type of 
fat, with the 100% WPHP consisting of predominantly 
medium-chain triglycerides (MCTs) compared to the 
other 2 formulas (50% WWP and casein formula), which 
predominantly contained long-chain triglycerides (LCTs) 
(Table 1). Parents and staff undertaking investigations 
and questionnaires were blinded to all formulas.
Statistical Analysis
All results have been reported as the median value (inter-
quartile range). SigmaStat 11.0 software (SPSS, Inc, an 
IBM Company, Chicago, IL) was used to perform the sta-
tistical analyses. The Wilcoxon signed-ranks test was used 
to compare significance for the whole group (n = 13; ie, 
casein vs whey). The Mann-Whitney rank sum test was 
used to test for a difference in effect between the 2 differ-
ent whey-based formulas. A Spearman rank correlation was 
used to compare GE and reported symptoms/pain.
Results
Thirteen children were enrolled in the study, and all com-
pleted the GE breath tests (n = 13) and symptoms report-
ing (n = 13). The parent of 1 child declined to complete 
the impedance-pH study, and 1 impedance-pH study 
could not be analyzed due to catheter malfunction (n = 11).
Reflux
As a combined group, there was no significant difference 
between casein and whey formula for total reflux episodes 
(55 [10-111] vs 29 [16-142]) or reflux pH index (0 [0-1.7] 
vs 0.7 [0-2.6]), respectively, nor was there a difference 
between the 2 whey formulas (Table 2).
Gastric Emptying
Median GE t1/2 as a combined group was 40% faster with 
a whey formula (33.9 [25.3-166.2] min) compared to the 
casein formula (56.6 [46-191] min) (P = .033). Both of 
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the whey formulas produced a similar acceleration in GE 
compared to the casein formula (Table 3). Five of the 13 
patients (39%) who had delayed GE with the casein-based 
formula normalized with 1 of the whey formulas (using 
the age-related reference range20).
Symptoms and Pain
Median number of stools per day (recorded on the daily 
parent recording sheet) was unchanged between the casein 
vs whey formulas (0.8 [0.36-1.07] vs 0.86 [0.31-1.22], 
respectively), and there was also no difference in stool fre-
quency between the 2 whey formulas. Individual symptoms 
of gagging, regurgitation, irritability, pain, or constipation 
(reported using the VAS) revealed no differences between 
scores for casein vs whey formulas. When the 5 individual 
symptoms (score out of 10 for each) were combined to 
produce an aggregate score (minimum score 0, maximum 
score 50 for each patient), again there was no difference 
between scores for casein vs whey formulas (4.5 [0-8.6] vs 
3 [0-17], respectively). However, when comparing the 2 
whey formulas, although there was no difference during 
the casein week, aggregate scores for reported symptoms 
were significantly lower in children who received the 50% 
WWP vs 100% WPHP (Table 3). There was no correlation 
between the acceleration in GE and reduction in symp-
toms in the 50% WWP group (r = 0.49, P = .356).
Reports of pain (using the 3 assessment methods) 
were combined to produce an aggregate median score, 
which revealed that the overall level of pain was not dif-
ferent from the casein to the whey week (8.7 [1.2-17.9] 
vs 11 [2.5-32.7], respectively). However, when comparing 
the 2 whey formulas, although there was no difference 
during the casein week, aggregate scores for reported pain 
were significantly lower in children who received the 50% 
WWP vs those who received 100% WPHP, whose pain 
scores worsened (Table 3).
Discussion
This study investigated the effect of a casein- vs whey-
based enteral formula on GOR, GE, and symptoms in 
children who have severe CP with a gastrostomy and 
Table 1.  Nutrition Comparison of the Casein Formula, 50% Whey Whole Protein Formula, and 100% Whey 
Partially Hydrolyzed Formula
Formula Analysis per 100 mL
Casein Based  
(82% Casein, 18% Whey)
50% Whey Whole Protein 
(50% Whey, 50% Casein)
100% Whey Partially  
Hydrolyzed Protein
Energy, kcal 100 100 100
Protein, g 3 3 3
Type Whole Whole Peptides
Source 82% casein 18% whey 50% casein 50% whey 100% whey
Carbohydrate, g 11.0 13.3 13.8
Source Maltodextrin (corn), sucrose Maltodextrin (corn), sucrose,  
corn syrup
Maltodextrin (corn), sucrose, 
starch
Fat, g 5 4 3.9
LCT, % 80 79 40
 Source High oleic sunflower oil,  
soya oil
High oleic sunflower oil, low erucic 
rapeseed oil, corn oil, soya lethicin
Soya oil, high oleic sunflower 
oil, soya lecithin
MCT, % 20 21 60
Fiber 0 0 0
Osmolality, mOsm/kg water 350 350 380
LCT, long-chain triglyceride; MCT, medium-chain triglyceride.
Table 2.  Median (Interquartile Range) Values for Total Reflux, Acid and Nonacid Episodes, and Reflux Index Over 
the 24-Hour Period for Casein vs 50% Whey Whole Protein (WWP; n = 5) and Casein vs 100% Whey Partially 
Hydrolyzed Protein (WPHP; n = 6)
Casein (n = 5) 50% WWP Casein (n = 6) 100% WPHP
Total reflux episodes 55 (24.5-194.5) 32 (17.5-194) 41.5 (9-87.5) 25.5 (14.3-68.3)
Acid episodes 1 (0-26.5) 0 (0-36) 1 (0-9.5) 2 (0-8.5)
Nonacid episodes 39 (24-176) 32 (13-162) 23.5 (8.3-87.3) 14.5 (12-68)
Reflux pH index 0.5 (0-1.9) 0 (0-5.9) 0 (0-1.7) 0.7 (0-2.6)
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fundoplication. We observed that the whey-based formula 
(compared to casein) accelerated GE, but this improve-
ment in GE did not alter GOR frequency or GI symp-
toms.
Few studies have examined the GI function of CP 
children, especially with respect to nutrition manipula-
tion of the enteral formula. Those that have vary signifi-
cantly in the quality of the experimental design. Criticisms 
of previous study designs include lack of randomization, 
blinding, control for positioning of the child, control for 
nutrition status,22 and control for variables in the formula 
constitution, including protein, lipid, and carbohydrate 
concentrations; osmolality; and caloric density. We aimed 
to minimize as many variables as possible (with what was 
commercially available), with our formulas only differing 
in the amount of whey, protein fractionation, and type of 
fat. As we were unable to commercially source a pre-
dominantly whey-based formula (whole protein), we stud-
ied 2 whey formulas with 50% WWP and 100% WPHP 
(Table 1).
Our study is the first to investigate pH impedance–
measured GOR in CP children. Standard pH probes, 
which are still common practice, have significant limita-
tions23-25 as it is likely that much of the refluxate is missed 
because of frequent milk-based enteral feeding, which 
buffers gastric pH. Using pH impedance, we found that 
indeed most of the reflux episodes in these children were 
nonacid. However, we found no effect of whey vs casein 
in reducing acid, nonacid, total reflux episodes, and pH 
index. It must be noted, however, that because of an 
increase in fundoplication surgery performed together 
with gastrostomy,26 all but 1 child had undergone fundop-
lication. We predict this would have markedly reduced 
the amount of overall reflux in the cohort, making it dif-
ficult to demonstrate further reductions in GOR in rela-
tion to a feeding intervention. It is therefore not surprising 
that our findings contrast with the study of Khoshoo et al,14 
who studied CP children with GOR symptoms but with-
out fundoplication and showed a significant reduction in 
acid GOR episodes (by pH-metry) with a whey-based 
enteral formula (P < .05).
In relation to GE and whey-based formulas, the small 
amount of research is suggestive of whey formulas accel-
erating GE in children with CP.13 GE of 3 whey-based 
formulas (compared to casein) was studied in 9 CP chil-
dren with GOR. A significant acceleration in GE was 
found with all whey formulas compared to casein (P < 
.001).13 Despite the 3 whey formulas varying in amount 
of whey protein, protein concentration, protein fractiona-
tion, presence of LCT vs MCT, caloric density, and osmo-
lality, they showed no significant difference between 
them in their effect on GE. Similarly, a pilot study of 15 
enterally fed children with CP showed a significant accel-
eration in mean GE t1/2 (measured by 
13C-Na-octanoate 
breath test) with a 60% whey formula compared to a 
casein-based formula (P < .001).12
Although we found a significant improvement in GE 
with the whey formula, whether or not this translates into 
improved enteral feed tolerance is an important question. 
We found no difference in GI symptoms between casein 
vs whey, but we found a significant difference between 
the 2 whey formulas, with the children consuming the 
50% WWP experiencing less symptoms than those con-
suming the 100% WPHP. Graham-Parker,27 who studied 
children with severe CP (aged 2–9 years), found that 
children consuming a 50% whey formula had significantly 
less reported gagging and retching (but not vomiting) 
compared to those consuming a casein-based formula (P 
< .001).
We found no correlation between the acceleration in 
GE and improvement in pain or symptoms in the 50% 
WWP group and in fact a worsening of these scores in the 
100% WPHP group (despite accelerated GE). It is not 
known whether this is a function of small sample size or 
whether another factor is influencing GI symptoms. Why 
the 100% WPHP group in our study experienced signifi-
cantly greater pain and symptoms scores compared to the 
50% WWP is unclear. It could be hypothesized that the 
higher MCT content of the 100% WPHP formula (com-
pared to 50% WWP or casein), which was the biggest 
variable between all formulas, may possibly contribute to 
the increased symptoms in this population. The daily dosage 
Table 3.  Median (Interquartile Range) Scores for GE t1/2 (minutes), Aggregate VAS Symptoms, and Aggregate Pain 
Scores for the Casein Formula and 2 Whey Formulas
Casein (n = 7) 50% WWP Casein (n = 6) 100% WPHP
GE t1/2, min 56.6 (56-394.9) 33.1 (27.5-187.1) 59.5 (24-86) 39 (22.5-90.6)
Aggregate VAS symptoms score 4.7 (0-9.2) 0 (0-11.8)* 3.5 (0-13.0) 13.0 (2.5-24.8)*
Aggregate pain score 6.4 (0-19.6) 3.0 (2.0-11.0)** 9.1 (1.3-23.5) 32.7 (11.8-43.4)**
Those on 50% WWP had significantly lower reported symptoms score (*P = .035) and lower pain score (**P = .014) compared to those 
on 100% WPHP. GE, gastric emptying; VAS, visual analog scale; WPHP, whey partially hydrolyzed protein; WWP, whey whole protein.
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of MCT that is well tolerated by individuals is not well 
documented, and there are conflicting data regarding the 
tolerable doses that avoid GI upset.28,29
In conclusion, our pilot study shows that in children 
who have severe CP with a gastrostomy and fundoplication, 
GE of whey-based enteral formulas is significantly faster 
than casein-based formulas. A 50% whey whole-protein 
formula is better tolerated with less GI symptoms and 
pain than a 100% whey partially hydrolyzed formula. The 
acceleration in GE does not alter GOR frequency and does 
not correlate with symptomatic improvement. Our results 
indicate that enteral formula selection may be particularly 
important for children with severe CP and delayed GE.
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